Exploiting Pharmacokinetic Models of Tamoxifen and Endoxifen to Identify Factors Causing Subtherapeutic Concentrations in Breast Cancer Patients

被引：0
|
作者：
Lena Klopp-Schulze
Markus Joerger
Sebastian G. Wicha
Rob ter Heine
Chantal Csajka
Zinnia P. Parra-Guillen
Charlotte Kloft
机构：
[1] Freie Universitaet Berlin,Department of Clinical Pharmacy and Biochemistry, Institute of Pharmacy
[2] Cantonal Hospital,Department of Medical Oncology and Haematology
[3] Radboud University Medical Centre,Department of Pharmacy
[4] University Hospital Center and University of Lausanne,Division of Clinical Pharmacology and Toxicology, Service of Biomedicine
[5] University of Hamburg,Institute of Pharmacy
来源：
Clinical Pharmacokinetics | 2018年 / 57卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：229 / 242
页数：13
相关论文
共 50 条
  • [31] The impact of endoxifen-guided tamoxifen dose reductions on endocrine side-effects in patients with primary breast cancer
    Buijs, S. M.
    Oomen-de Hoop, E.
    Braal, C. L.
    van Rosmalen, M. M.
    Drooger, J. C.
    van Rossum-Schornagel, Q. C.
    Vastbinder, M. B.
    Koolen, S. L. W.
    Jager, A.
    Mathijssen, R. H. J.
    ESMO OPEN, 2023, 8 (01)
  • [32] Improved Prediction of Endoxifen Metabolism by CYP2D6 Genotype in Breast Cancer Patients Treated with Tamoxifen
    Schroth, Werner
    Winter, Stefan
    Muerdter, Thomas
    Schaeffeler, Elke
    Eccles, Diana
    Eccles, Bryony
    Chowbay, Balram
    Khor, Chiea C.
    Tfayli, Arafat
    Zgheib, Nathalie K.
    Eichelbaum, Michel
    Schwab, Matthias
    Brauch, Hiltrud
    FRONTIERS IN PHARMACOLOGY, 2017, 8
  • [33] Correction to: Influence of green tea consumption on endoxifen steady-state concentration in breast cancer patients treated with tamoxifen
    C. Louwrens Braal
    Koen G. A. M. Hussaarts
    Lieke Seuren
    Esther Oomen‑deHoop
    Peter de Bruijn
    ·Stefan A. J. Buck
    Monique E. M. M. Bos
    Martine F. Thijs‑Visser
    Hanneke J. M. Zuetenhorst
    Daniëlle Mathijssen‑van Stein
    Mijntje B. Vastbinder
    Roelof W. F. van Leeuwen
    Teun van Gelder
    Stijn L. W. Koolen
    Agnes Jager
    Ron H. J. Mathijssen
    Breast Cancer Research and Treatment, 2021, 185 : 889 - 889
  • [34] Aging may be associated with concentrations of tamoxifen and its metabolites in breast cancer patients
    Sheth, HR
    Lord, G
    Tkaczuk, K
    Danton, M
    Lewis, LM
    Langenberg, P
    Lim, CK
    Flaws, JA
    JOURNAL OF WOMENS HEALTH, 2003, 12 (08) : 799 - 808
  • [35] Volumetric Absorptive Microsampling as a New Biosampling Tool for Monitoring of Tamoxifen, Endoxifen, 4-OH Tamoxifen and N-Desmethyltamoxifen in Breast Cancer Patients
    Maggadani, Baitha Palanggatan
    Harmita
    Haryono, Samuel J.
    Rinaldi, Marcellino Ryan
    Harahap, Yahdiana
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2021, 15 : 2417 - 2430
  • [36] Exploiting novel models of endocrine-resistant breast cancer to identify new therapeutic targets
    Soosainathan, Arany
    Nikitorowicz-Buniak, Joanna
    Pancholi, Sunil
    Iravani, Marjan
    Alexander, John
    Haider, Syed
    Johnston, Stephen R.
    Dowsett, Mitchell
    Martin, Lesley A.
    Isacke, Clare M.
    CANCER RESEARCH, 2022, 82 (04)
  • [37] Variations in plasma concentrations of tamoxifen metabolites and the effects of genetic polymorphisms on tamoxifen metabolism in Korean patients with breast cancer
    Woo, Hye In
    Lee, Se Kyung
    Kim, Jiyoung
    Kim, Seok Won
    Yu, Jonghan
    Bae, Soo Youn
    Lee, Jeong Eon
    Nam, Seok Jin
    Lee, Soo-Youn
    ONCOTARGET, 2017, 8 (59) : 100296 - 100311
  • [38] Value of therapeutic drug monitoring of endoxifen in Egyptian premenopausal patients with breast cancer given tamoxifen adjuvant therapy: A pilot study
    EL Desoky, Ehab S.
    Taha, Amira F.
    Mousa, Heba Salah
    Ibrahim, Abeer
    Saleh, Medhat A.
    Abdelrady, Mohamed A.
    Hareedy, Mohammad Salem
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2023, 29 (07) : 1673 - 1686
  • [39] Optimized CYP2D6 phenotype assignment for plasma endoxifen prediction in breast cancer patients treated with tamoxifen
    Schroth, Werner
    Winter, Stefan
    Eichelbaum, Michel
    Muerdter, Thomas
    Schwab, Matthias
    Brauch, Hiltrud
    CANCER RESEARCH, 2017, 77
  • [40] Phase clinical trial of alitretinoin and tamoxifen in breast cancer patients: Toxicity, pharmacokinetic, and biomarker evaluations
    Lawrence, JA
    Adamson, PC
    Caruso, R
    Chow, C
    Kleiner, D
    Murphy, RF
    Venzon, DJ
    Shovlin, M
    Noone, M
    Merino, M
    Cowan, KH
    Kaiser, M
    O'Shaughnessy, J
    Zujewski, JA
    JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (10) : 2754 - 2763
12345